CERFLUX Announces Breast Cancer Research Foundation of Alabama Award

Share Article

Grant will support advanced imaging technology at the CerFlux lab.

CerFlux, creators of an advanced personalized medicine solutions to identify the most efficient and effective cancer treatments for each patient on an individualized basis, announced today the receipt of a $50,000 Breast Cancer Research Foundation of Alabama (BCRFA) grant to help fund new imaging technology at the CerFlux lab in downtown Birmingham.

This imaging technology will provide the added efficiency critical for processing breast cancer tumor specimens in the CerFlux Personalized Oncology Efficacy Test (POET). The personalized medicine approach at the heart of POET addresses the critical, urgent, and unmet need for accessible and affordable predictive tools that identify optimal systemic therapy regimens and eliminate ineffective options. By providing an individualized treatment plan, oncologists can improve a patient’s quality of life and reduce the stress of overtreatment on the patient.

“Nearly 300,000 people in the US will be diagnosed with breast cancer this year and potentially 70% of these patients will be treated with drugs that do not work for them. That is because each tumor is different and responds to treatment differently. Our goal is to predict which treatment options will work best – and which ones will not work – for each patient on an individualized basis prior to initiating treatment,” explains CerFlux CEO Dr. Karim Budhwani.

"The BCRFA is pleased to again support the promising research being conducted by the CerFlux team," said Beth Bradner Davis, Executive Director of the Breast Cancer Research Foundation of Alabama. "Our organization's core mission is to find and fund projects that have a deep impact on breast cancer patients in Alabama and around the globe. CerFlux Personalized Oncology Efficacy Test (POET) is making great advances in treatment for cancer patients. We are proud to continue our partnership."

Development of the CerFlux POET predictive technology will transform cancer treatment in the near-term and make a difference in the lives of patients and providers around the world. The POET is designed to be a low-cost and rapid testing option to match each patient with the right treatment BEFORE a treatment regimen begins. Every year, the need for such personalized medicine technology in breast cancer treatment is amplified 300,000 times.

POET is a promising innovation – from Alabama – that could transform cancer treatment and make a significant impact on the lives of cancer patients worldwide.

The CerFlux mission to #CrushCancer is vital to the ways we can improve cancer treatment. Cancer is pervasive as nearly half the world will be diagnosed with cancer including more than 1.7 million annual diagnoses in the US alone.

Nearly 70% of patients are treated with what turn out to be ineffective first-line therapeutics because those drugs do not match the patient’s tumor, imposing a substantial physical, emotional, and financial burden on the patient and their families. CerFlux POET will fill the gap in the lack of clinically relevant, personalized efficacy evaluation tools that can reduce treatments based on generalized parameters that potentially expose patients to several rounds of ineffective therapy. POET has the potential to reduce delays and ineffective treatments by leading to effective treatment options to increase overall survival.

About CerFlux, Inc.
At CerFlux we are creating advanced personalized medicine solutions to identify the most efficient and effective cancer treatments for each patient on an individualized basis. Currently, CerFlux is currently working with partners on matching treatments to tumors for lung, pancreatic, ovarian, breast, and colorectal cancers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rebecca Dobrinski
CerFlux, Inc.
+1 (855) 500-0040 Ext: 413
Email >
Visit website

Media